| I-62 Silvia Grandoni Therapeutic effect of anti-IL6 monoclonal antibodies in the treatment of COVID-19 in adults and multisystem inflammatory syndrome in children using siltuximab as a case study |
| I-63 Charlotte Kern Modeling changes in SARS-CoV-2 variants within-host transmissibility on antiviral drug effect |
| I-64 Timothy Knab A Physiologically-based Pharmacokinetic Modeling Approach to Support Candidate and First in Human Dose Selection for Bamlanivimab |
| I-65 Tarunendu Mapder Antiviral Treatment on SARS-Cov-2 Infected Epithelial Tissue Patch |
| I-66 Aurélien MARC Developing a model of SARS-CoV-2 viral dynamics under monoclonal antibody treatment. |
| I-67 Dirk Jan Moes Towards fixed dosing of tocilizumab in ICU admitted COVID-19 patients; results of an observational population pharmacokinetic and descriptive pharmacodynamic study |
| I-68 Venkatesh Pilla Reddy Application of modelling and simulation in development of an antibody cocktail for the prevention and treatment of COVID-19 |
